全文获取类型
收费全文 | 23195篇 |
免费 | 1748篇 |
国内免费 | 802篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 259篇 |
妇产科学 | 158篇 |
基础医学 | 1328篇 |
口腔科学 | 303篇 |
临床医学 | 1807篇 |
内科学 | 2967篇 |
皮肤病学 | 306篇 |
神经病学 | 1989篇 |
特种医学 | 314篇 |
外国民族医学 | 2篇 |
外科学 | 893篇 |
综合类 | 2702篇 |
一般理论 | 3篇 |
预防医学 | 1398篇 |
眼科学 | 190篇 |
药学 | 8965篇 |
8篇 | |
中国医学 | 1312篇 |
肿瘤学 | 770篇 |
出版年
2024年 | 71篇 |
2023年 | 363篇 |
2022年 | 546篇 |
2021年 | 792篇 |
2020年 | 766篇 |
2019年 | 823篇 |
2018年 | 832篇 |
2017年 | 888篇 |
2016年 | 815篇 |
2015年 | 815篇 |
2014年 | 1599篇 |
2013年 | 2363篇 |
2012年 | 1453篇 |
2011年 | 1530篇 |
2010年 | 1212篇 |
2009年 | 1025篇 |
2008年 | 985篇 |
2007年 | 1009篇 |
2006年 | 838篇 |
2005年 | 753篇 |
2004年 | 645篇 |
2003年 | 585篇 |
2002年 | 432篇 |
2001年 | 418篇 |
2000年 | 336篇 |
1999年 | 295篇 |
1998年 | 268篇 |
1997年 | 274篇 |
1996年 | 277篇 |
1995年 | 234篇 |
1994年 | 223篇 |
1993年 | 230篇 |
1992年 | 246篇 |
1991年 | 171篇 |
1990年 | 179篇 |
1989年 | 141篇 |
1988年 | 149篇 |
1987年 | 99篇 |
1986年 | 101篇 |
1985年 | 141篇 |
1984年 | 122篇 |
1983年 | 87篇 |
1982年 | 95篇 |
1981年 | 68篇 |
1980年 | 81篇 |
1979年 | 58篇 |
1978年 | 70篇 |
1977年 | 57篇 |
1976年 | 50篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
从脾论治磺脲类降糖药继发性失效 总被引:2,自引:0,他引:2
对 64例 2型糖尿病继发磺脲类降糖药失效患者 ,在继续口服磺脲类药的基础上加用健脾中药 ,结果显效 1 5例 ,有效 3 6例 ,无效 1 3例 ,总有效率 85 .2 4% ;治疗前后血糖明显下降 ,有显著性差异 ( P<0 .0 0 1 ) 相似文献
63.
64.
临床医师处方抗菌药物前需思考的几个问题 总被引:20,自引:0,他引:20
2001年和2003年卫生部全国医院感染监测网调查结果均显示,医院横断面抗菌药物的平均使用率在54%以上,联合用药较为普遍.国内监测结果也表明细菌耐药性日益严重.针对上述问题,提出临床医师在面对病人开处方抗菌药物之前,须思考的问题:是否有使用抗菌药物的适用症?是否了解选用的抗菌药物,选用何种药物?是否有联合使用抗菌药物的指征?采用何种给药途径、给药剂量、给药时间?是否属于特殊宿主或针对特殊病原体的感染使用抗菌药物?密切观察抗菌药物治疗是否有效?针对局部感染是否需要穿刺或外科手术引流病灶?是否已出现抗菌药物的不良反应?是否存在药物相互作用?是否存在不合理使用抗菌药物情况?并且针对每个问题提出了建议. 相似文献
65.
Nonpigmenting fixed exanthema from ephedrine and pseudoephedrine 总被引:2,自引:2,他引:0
66.
P C G?tzsche 《Journal of clinical epidemiology》1990,43(12):1313-1318
In a meta-analysis of placebo controlled NSAID trials, the sensitivity of the effect variables was calculated as the correlation coefficient and as the difference between drug and placebo, divided by the placebo group standard deviation. The patient's global evaluation was the most sensitive variable overall. Pain was more sensitive than Ritchie's index. Several variables may be omitted from clinical trials, especially if two active drugs are being compared. For example, the best maximum estimate for the difference in ESR between NSAADs and placebo was 1.0 mm/hr (95% confidence interval −1.5 to 3.4 mm/hr), and for joint size 0.44% (−1.0 to 1.9%), corresponding to a quarter of a millimeter for each of the 10 joints usually measured. It is suggested to record only the patient's global evaluation, pain, and morning stiffness. 相似文献
67.
68.
Abstract: Elevated lipoprotein concentrations seem to be linked strongly in a dose dependent manner to an increased incidence of atherosclerosis. A total of 47 patients suffering from severe hyperlipidemia were matched to treatment with LDL apheresis (Baxter, Kaneka, Li–popak; 24 patients, aged 50.2 ±11.5 years), diet, and/or lipid–lowering drugs or with diet and lipid–lowering drugs only (23 patients, aged 48.8 ±11.8 years). After treatment periods of 49.8 ±13.4 months (apheresis group, 2,396 treatment sessions) and 38.6 ± 15.1 months (drug group), the ensuing results revealed significant differences (p <0.0001): –47.3% versus –12.1% for total cholesterol, –46.9% versus –21.8% for LDL, +8.4% versus +0.9% for HDL, –52.0% versus – 13.1% for the LDL/HDL ratio, –36.4% versus –16.2% for triglycerides, and –25.9% versus + 1.5% for lipoprotein (a). In the apheresis group, one patient died of myocardial infarction; in the drug group, there was one nonfatal myocardial infarction and the manifestation of coronary heart disease in 3 cases. There were no severe side effects in either group. All patients in the apheresis group responded to therapy. The present trial suggests that a continuing reduction in serum lipid concentrations may lower, in a dose dependent manner, the risk for development and progression of coronary heart disease. Regarding clinical and laboratory results, LDL apheresis seems to be safe, effective therapy for treatment of severe hyperlipidemia. 相似文献
69.
用荧光探剂DPH研究家蝇线粒体膜脂流动性 总被引:1,自引:0,他引:1
曾晓Peng 《中国媒介生物学及控制杂志》1996,7(2):89-94
本文探讨了用DPH作为荧光探剂,研究家蝇飞翔肌线粒体膜脂流动性的方法。实验表明:DPH确是用来研究家蝇生物膜流动性的有效探剂。同时,初步观察了不同杀虫剂对DPH与线粒体膜结合后荧光强度的影响。其中氯菊酯和倍硫磷、马拉硫磷、敌百虫、氧化乐果,可使DPH探剂与线粒体膜结合后的荧光相对强度增加;而氰戊菊酯、氯氰菊酯,溴氰菊酯及辛硫磷、乙酰甲胺磷,则可使荧光强度减弱。 相似文献
70.
Allen Cato III Linda E. Gustavson Jiang Qian Tawakol El-Shourbagy Edward A. Kelly 《Epilepsia》1998,39(1):43-47
Summary: Purpose: We wished to determine the effect of renal impairment on the pharmacokinetics and tolerability of the new antiepileptic drug tiagabine (TGB).
Methods: We assessed TGB pharmacokinetics and tolerability in 25 subjects with various degrees of renal function (based on creatinine clearance, n = 4–6 per group) from healthy (group I) to requiring hemodialysis (group V) in a single and multiple dose (every 12h), one-period (groups I-IV) or a single dose, two-period (group V) study (4-mg oral doses of TGB · HCl). Blood samples were collected after the first dose (both periods for group V) and after the last dose on day 5 (groups I-IV). TGB plasma concentrations and plasma protein binding were determined by high-performance liquid chromatography (HPLC) and ultrafiltration, respectively.
Results: TGB was well tolerated by all study subjects. The pharmacokinetics of TGB were similar in all subjects; no pharmacokinetic parameter (based on either total or unbound concentrations) was statistically correlated with creatinine clearance. For total TGB in plasma, single-dose mean values of the maximum plasma concentration, clearance, and half-life (t1/2) ranged from 52 to 108 ng/ml, from 7.14 to 11.02 I/h, and from 6.4 to 8.4 h, respectively.
Conclusions: TGB pharmacokinetics and tolerability were independent of renal function; therefore, dosage adjustment is unnecessary for epilepsy patients with renal impairment. 相似文献
Methods: We assessed TGB pharmacokinetics and tolerability in 25 subjects with various degrees of renal function (based on creatinine clearance, n = 4–6 per group) from healthy (group I) to requiring hemodialysis (group V) in a single and multiple dose (every 12h), one-period (groups I-IV) or a single dose, two-period (group V) study (4-mg oral doses of TGB · HCl). Blood samples were collected after the first dose (both periods for group V) and after the last dose on day 5 (groups I-IV). TGB plasma concentrations and plasma protein binding were determined by high-performance liquid chromatography (HPLC) and ultrafiltration, respectively.
Results: TGB was well tolerated by all study subjects. The pharmacokinetics of TGB were similar in all subjects; no pharmacokinetic parameter (based on either total or unbound concentrations) was statistically correlated with creatinine clearance. For total TGB in plasma, single-dose mean values of the maximum plasma concentration, clearance, and half-life (t1/2) ranged from 52 to 108 ng/ml, from 7.14 to 11.02 I/h, and from 6.4 to 8.4 h, respectively.
Conclusions: TGB pharmacokinetics and tolerability were independent of renal function; therefore, dosage adjustment is unnecessary for epilepsy patients with renal impairment. 相似文献